|
|
Vaccine Detail
|
VEGFR-2 DNA Vaccine VXM01 |
| Vaccine Information |
- Vaccine Name: VEGFR-2 DNA Vaccine VXM01
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007008
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- VEGFA
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- KDR
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The oral T cell vaccine VXM01 consists of live, attenuated Salmonella typhi carrying a eukaryotic expression plasmid that encodes for full length vascular endothelial growth factor receptor 2 (VEGFR2) (Schmitz-Winnenthal et al., 2018).
- Description: This is for Brain Cancer (NCT02718443). An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial growth factor receptor 2 (VEGFR-2) (VXM01), with potential immunomodulating, anti-angiogenic and antineoplastic activity. Upon oral administration and successful transduction, VEGFR-2 DNA vaccine VXM01 expresses VEGFR-2 in addition to inducing the expression of T-cell activation markers, such as CD25, interleukin-2, the early T-cell activation antigen CD69 and the lymphocyte function-associated antigen LFA-2. The immune response targets the fast growing VEGFR-2 expressing endothelial cells found in the tumor vasculature, thereby blocking angiogenesis which may ultimately inhibit tumor cell proliferation. VEGFR-2 is a receptor tyrosine kinase overexpressed on proliferating endothelial cells in the tumor vasculature (Schmitz-Winnenthal et al., 2018; NCIT_C99378).
|
| Host Response |
|
|
| References |
NCIT_C99378: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99378]
NCT02718443: [https://clinicaltrials.gov/show/NCT02718443]
Schmitz-Winnenthal et al., 2018: Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. Oncoimmunology. 2018; 7(4); e1303584. [PubMed: 29632710].
|
|
